Editorial: anti-TNF combination therapy for inflammatory bowel disease-one size does not fit all
Aliment Pharmacol Ther
.
2022 Mar;55(6):750-751.
doi: 10.1111/apt.16803.
Authors
Edo H J Savelkoul
1
,
Frank Hoentjen
2
Affiliations
1
Radboud University Medical Centre, Nijmegen, the Netherlands.
2
Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada.
PMID:
35245960
DOI:
10.1111/apt.16803
No abstract available
Publication types
Editorial
Comment
MeSH terms
Humans
Inflammatory Bowel Diseases* / drug therapy
Infliximab / therapeutic use
Tumor Necrosis Factor Inhibitors* / therapeutic use
Substances
Tumor Necrosis Factor Inhibitors
Infliximab